advanced search

INJECTION

Drug Delivery Devices Past and Future: A Retrospective on Innovation, Achievement and Hard Lessons
INJECTION
Tom Oakley
Sanner Group
Drug Delivery Devices Past and Future: A Retrospective on Innovation, Achievement and Hard Lessons
Tom Oakley and Ulrich Bruggemann discuss the innovations that featured novel forms of drug delivery for patients, but either failed to succeed commercially or even reach the market.
MASTERING PRODUCT TRANSFER FOR A RANGE OF INJECTABLES
SHOWCASE
Lifecore Injectables
MASTERING PRODUCT TRANSFER FOR A RANGE OF INJECTABLES
Lifecore Injectables explores product transfer, the often overlooked step between formulation and filling, and looks at how transfer technologies, mixing and recirculation strategies can be matched to the demands of water-like solutions, highly viscous products and fast-settling suspensions to maintain product quality throughout manufacturing.
Interview: Eco-Inject: Bringing Affordable Sustainability to Single-Use Disposable Autoinjectors
INTERVIEW
Michael Earl
Eco-inject
Interview: Eco-Inject: Bringing Affordable Sustainability to Single-Use Disposable Autoinjectors
In this exclusive interview, Michael Earl and Steven Kaufman speak about the significant progress Eco-Inject has made throughout 2026 since its highly successful funding round earlier in the year, discussing what’s new in the world of Eco-Inject, what sets the device platform apart from other approaches to sustainability in the autoinjector space, and how the industry is reacting to Eco-Inject as it moves towards the market.
END-OF-DOSE CLICK-BAIT: HARDER THAN IT SOUNDS
INJECTION
Peter McGrattan
Team Consulting
END-OF-DOSE CLICK-BAIT: HARDER THAN IT SOUNDS
Peter McGrattan focuses in on the particular challenge of engineering an end-of-dose click for autoinjectors, examining the key design tensions, increasing regulatory attention, the trade-offs between different power mechanisms and how potential alternative feedback mechanisms may play into the design.
PLATFORMS IN BIOPHARMA DEVICE DEVELOPMENT: FROM PRACTICE TO STRATEGY
EXPERT VIEW
Tim Quigg
PLATFORMS IN BIOPHARMA DEVICE DEVELOPMENT: FROM PRACTICE TO STRATEGY
Tim Quigg, Katie Ogden with Dr Shirish Ingawale discuss some of the key points from the 2026 PFS & Injectable Drug Devices East Coast Conference regarding biopharma platform technology.
ASSEMBLY CONCEPTS FOR WEARABLE INJECTORS BASED ON ROI
INDUSTRIALISATION
Dr Carsten Köhler
BBS Automation
ASSEMBLY CONCEPTS FOR WEARABLE INJECTORS BASED ON ROI
Dr Carsten Köhler looks at how assembly concepts drive the return on investment in the wearable injectors market and the effect of automation on these metrics.
THE COMMERCIAL CASE FOR SPRAY-DRYING FOR MODERN DRUG PIPELINES
INDUSTRIALISATION
Itay Speicher
Catalent Pharma Solutions
THE COMMERCIAL CASE FOR SPRAY-DRYING FOR MODERN DRUG PIPELINES
Catalent's Itay Speicher highlights how current conditions in the pharmaceutical pipeline, especially the high proportion of poorly soluble drugs in early-stage development and rise in amorphous solid dispersions, along with the cost-efficiency and flexibility of spray-drying, are providing the optimal conditions to maximise the value of spray-drying in drug development and commercial scale-up.
SIMPLIFYING COMBINATION THERAPIES: DUAL-INJECTION FUNCTIONALITY FOR EXISTING PLATFORM AUTOINJECTOR SYSTEMS
DUAL CHAMBER
Marc Flippe
BD (Becton Dickinson & Company)
SIMPLIFYING COMBINATION THERAPIES: DUAL-INJECTION FUNCTIONALITY FOR EXISTING PLATFORM AUTOINJECTOR SYSTEMS
Marc Flippe and Sophie Lelias discuss how dual-injection technology provides a promising approach to combination therapies and explain how, through the development of BD’s novel valve component, the company has reimagined dual injection within existing and established platform systems.
AHEAD OF THE CURVE: How Innovation Without Change<sup>®</sup> Delivers an End-to-End DUAL-CHAMBER Solution
DUAL CHAMBER
Sian Eden
Credence MedSystems
AHEAD OF THE CURVE: How Innovation Without Change® Delivers an End-to-End DUAL-CHAMBER Solution
Sian Eden and John Merhige consider how dual-chamber solutions have moved from a niche product to a mainstream consideration for stability-challenged formulations, offering formulation teams an alternative path to get these promising therapies into the hands of the patients that need them, and highlight how Credence is uniquely positioned to deliver on the potential of dual-chamber systems.
The Missing Middle of SC Drug Delivery: How a Dual-Cartridge Architecture Could Unlock the 3–10 mL Opportunity
DUAL CHAMBER
Dr Brent Buchine
Windgap Medical
The Missing Middle of SC Drug Delivery: How a Dual-Cartridge Architecture Could Unlock the 3–10 mL Opportunity
Dr Brent Buchine, Mike Ratigan and Aaron Mann argue that the industry’s traditional 2–3 mL boundary for subcutaneous injection reflects the limitations of conventional device and primary-container architectures more than the needs of any particular product or patient, considering whether two widely available cartridges, integrated into a single handheld system, could extend the simplicity and range of autoinjection.
Interview: Rethinking Drug Delivery for Increasingly Complex Therapies
INTERVIEW
Ram Halthore
KALEO
Interview: Rethinking Drug Delivery for Increasingly Complex Therapies
In this interview, Ram Halthore discusses the demands of newer classes of injectable drugs and the trend towards self-administration using conventional drug delivery systems, the requirements innovative systems must meet and the importance of selecting a delivery system early in formulation development, as well as the roles that robust human factors engineering and high reliability should play in device development.
LEVERAGING LARGE-VOLUME PLATFORMS FOR LIQUID-LIQUID DRUG DELIVERY
DUAL CHAMBER
Valerio Ravazzolo
Stevanato Group
LEVERAGING LARGE-VOLUME PLATFORMS FOR LIQUID-LIQUID DRUG DELIVERY
Valerio Ravazzolo and Thomas James examine liquid-liquid drug delivery using Stevanato Group’s EZ-fill® 3 mL internal-bypass cartridge platform and SHL Medical’s Magnitude 3.0 autoinjector platform, demonstrating how these technologies can be integrated into a standardised container-device ecosystem, helping to reduce the cost, risk and development timelines traditionally associated with customised solutions for combination products.
GAS-POWERED AUTOINJECTORS: MEETING THE CHALLENGES OF AN EVOLVING DRUG LANDSCAPE
DUAL CHAMBER
Ram Halthore
KALEO
GAS-POWERED AUTOINJECTORS: MEETING THE CHALLENGES OF AN EVOLVING DRUG LANDSCAPE
Ram Halthore presents Kaleo's Aerio™ autoinjector platform, discussing how gas-powered autoinjectors have the potential to tackle the challenges currently facing injectable drug delivery, including high-viscosity and large-volume formulations, increased demand for patient-centricity and stringent regulatory requirements for reliability in emergency-use applications.
CAPA VALVE LAUNCHES NEW VALVE SYSTEM FOR DUAL-CHAMBER DEVICES
DUAL CHAMBER
Dr Phil Green
Capa Valve
CAPA VALVE LAUNCHES NEW VALVE SYSTEM FOR DUAL-CHAMBER DEVICES
Dr Phil Green and Kevin Abbott discuss how Capa Valve’s patented valve technology provides a compelling alternative to bypass-based dual-chamber syringes, as its pressure-sensitive valve-based design enables much greater compatibility with existing fill-finish infrastructure and offers the flexibility to precisely tune the device via the geometric position of the valve within the syringe barrel.
PROACTIVE QUALITY AND REGULATORY ENGAGEMENT TO ACCELERATE PRODUCT DEVELOPMENT
PHARMA VIEW
Bharat Arora
PROACTIVE QUALITY AND REGULATORY ENGAGEMENT TO ACCELERATE PRODUCT DEVELOPMENT
Bharat Arora and Hirak Bhatiya Pharmaceuticals discuss the quality and regulatory perspective on accelerated development pathways transitioning from an emergency measure to a mainstream route to commercialisation, going over what may be expected of pharmaceutical quality teams to manage this new paradigm.
ENABLING DELIVERY OF LYOPHILISED BIOLOGICS VIA SIMULATION-LED DEVELOPMENT OF DUAL-CHAMBER SYSTEMS
EXPERT VIEW
Dr Sahab Babaee
ENABLING DELIVERY OF LYOPHILISED BIOLOGICS VIA SIMULATION-LED DEVELOPMENT OF DUAL-CHAMBER SYSTEMS
Dr Sahab Babaee and Dr Matthew Hancock discuss the potential of using modelling and simulation when designing dual-chamber injection devices, which can enable device designers to investigate the complex interactions that take place within a dual-chamber system without a physical prototype and discover potential failure modes much earlier in the design process.
UNSTACKING THE DUAL-CHAMBER SYRINGE: A CARTRIDGE-BASED PATH TO RELIABLE RECONSTITUTION
DUAL CHAMBER
Eric Sugalski
Ampulis
UNSTACKING THE DUAL-CHAMBER SYRINGE: A CARTRIDGE-BASED PATH TO RELIABLE RECONSTITUTION
Eric Sugalski and Tom Handel introduce Pristal, the cartridge-based reconstitution platform from Ampulis, and explain how it overcomes some of the usability, manufacturing and supply-chain challenges that have limited stacked dual-chamber syringes.
HIGH-CONCENTRATION, HIGH-VISCOSITY DELIVERY WITH CORE-ANNULAR FLOW
EARLY INSIGHT
Dr Simon Rufer
CoFlo Medical
HIGH-CONCENTRATION, HIGH-VISCOSITY DELIVERY WITH CORE-ANNULAR FLOW
Dr Simon Rufer and Pratik Mishra introduce CoFlo Medical ’s core-annular flow platform, which promises to eliminate the long-standing viscosity bottleneck for needle-based delivery. The company’s platform enables high-concentration, high-viscosity delivery for existing formulations without the need for reformulation or new compounds in a patient-friendly form.
RECONSTITUTION TO CO-DELIVERY: DESIGNING MULTICHAMBER DEVICES FOR BETTER PATIENT EXPERIENCES
EXPERT VIEW
Jack Dunkley
RECONSTITUTION TO CO-DELIVERY: DESIGNING MULTICHAMBER DEVICES FOR BETTER PATIENT EXPERIENCES
Jack Dunkley delves into the architectural principles of multichamber systems for injectable formulations and considers how to overcome the design challenges involved.
WHY SMARTER WEARABLES ARE THE SIMPLE ANSWER TO INTELLIGENT DRUG DELIVERY
WEARABLES
Dr Greg Moakes
LTS
WHY SMARTER WEARABLES ARE THE SIMPLE ANSWER TO INTELLIGENT DRUG DELIVERY
Dr Greg Moakes considers how complex devices, such as LTS’s Sorrel™ on-body delivery system can facilitate the self-administration of injectable therapies while continuously monitoring and verifying the device’s critical delivery functions.
SCALING ON-BODY DELIVERY FOR LARGE-VOLUME THERAPIES
WEARABLES
Dr Oliver Eden
TxSphere
SCALING ON-BODY DELIVERY FOR LARGE-VOLUME THERAPIES
Mike Stout and Dr Oliver Eden examine the shift towards large-volume SC administration, what on-body delivery systems make possible and why bringing them to market at scale depends as much on manufacturing as on design.
LIMITS SHATTERED: ENDING THE AUTOINJECTOR AND WEARABLE INJECTOR DIVIDE
WEARABLES
Dr Scott Russo
Synolus Medical
LIMITS SHATTERED: ENDING THE AUTOINJECTOR AND WEARABLE INJECTOR DIVIDE
Dr Scott Russo questions the distinction between wearable injectors and autoinjectors, making the case that it is not fundamental to device design, rather it is an outdated segmentation that results in unnecessary design trade-offs. He introduces MiniGo, a next-generation platform device that aims to overcome this false dichotomy.
Off The Critical Path: Bringing Device Strategy Forward In Combination Product Development
INTERVIEW
David Karvani
Ventura Solutions
Off The Critical Path: Bringing Device Strategy Forward In Combination Product Development
David Karvani and Greg Moakes discuss how early collaboration with device development partners can help pharma companies navigate the technical and regulatory complexities of combination product development.
INDUSTRIAL ARCHITECTURE: THE NEXT COMPETITIVE ADVANTAGE IN WEARABLE INJECTORS
EXPERT VIEW
Andy Wertheim
INDUSTRIAL ARCHITECTURE: THE NEXT COMPETITIVE ADVANTAGE IN WEARABLE INJECTORS
Andy Wertheim puts forward the case that wearable drug delivery devices comprise two separate architectures – therapeutic and industrial – that must be developed and implemented in tandem if a development programme is to achieve long-term commercial success.
Top